UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
October 12, 2017
|
||||
|
Date of Report (Date of earliest event reported)
|
||||
|
NU SKIN ENTERPRISES, INC.
|
||||
|
(Exact name of registrant as specified in its charter)
|
||||
|
Delaware
|
001-12421
|
87-0565309
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
||
|
75 West Center Street
Provo, Utah 84601
|
||||
|
(Address of principal executive offices and zip code)
|
||||
|
(801) 345-1000
|
||||
|
(Registrant's telephone number, including area code)
|
||||
|
N/A
|
||||
|
(Former name or former address, if changed since last report)
|
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
| □ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| □ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company □
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □
Item 2.02 Results of Operations and Financial Condition.
On October 12, 2017, Nu Skin Enterprises, Inc. (the "Company") issued a press release providing updated revenue and earnings per share guidance for the three-month period ended September 30, 2017, and certain other information. A copy of the Company's press release is attached as Exhibit 99.1 to this report and incorporated by reference.
The information furnished pursuant to this Item 2.02 and the exhibit hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibit.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NU SKIN ENTERPRISES, INC.
(Registrant)
(Registrant)
/s/ Mark H. Lawrence
Mark H. Lawrence
Chief Financial Officer
Chief Financial Officer
Date: October 12, 2017
FOR IMMEDIATE RELEASE
NU SKIN ENTERPRISES PROVIDES UPDATED Q3 REVENUE AND EPS GUIDANCE
PROVO, Utah — Oct. 12, 2017 — In connection with its Nu Skin LIVE! global convention beginning today, Nu Skin Enterprises (NYSE:NUS) provided updated third-quarter 2017 revenue and earnings guidance. The company expects revenue of $559 to $563 million, with anticipated earnings per share of $0.74 to $0.76.
Nu Skin's management team will discuss updated guidance, recent business trends and upcoming initiatives at an investor meeting today at 1:45 p.m. (ET). A live webcast of the investor meeting, including the financial and other information to be presented, will be available on the investor relations section of the company's website at ir.nuskin.com. Replays of the webcast will be available at the same location through Thursday, Oct. 26.
About Nu Skin Enterprises, Inc.
Founded more than 30 years ago, Nu Skin Enterprises, Inc. develops and distributes innovative consumer products, offering a comprehensive line of premium-quality beauty and wellness solutions. The company builds upon its scientific expertise in both skin care and nutrition to continually develop innovative product brands that include the Nu Skin® personal care brand, the Pharmanex® nutrition brand, and most recently, the ageLOC® anti-aging brand. The ageLOC brand has generated a loyal following for such products as the ageLOC Youth nutritional supplement, the ageLOC Me® customized skin care system, as well as the ageLOC TR90® weight management and body shaping system. Nu Skin sells its products through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific. As a long-standing member of direct selling associations globally, Nu Skin is committed to the industry's consumer guidelines that protect and support those who sell and purchase its products through the direct selling channel. Nu Skin is also traded on the New York Stock Exchange under the symbol "NUS." More information is available at nuskin.com.
(more)
Important Information Regarding Forward-Looking Statements: The updated guidance contained in this press release is a forward-looking statement within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and it represents the company's current expectations and beliefs. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from the forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, estimates and guidance concerning anticipated revenue and earnings per share, which can differ from actual results based on a number of factors, including higher-than-anticipated expenses, changes in reserves, subsequent events that have an impact on the third quarter, and quarter-end and other financial-statement or audit adjustments. The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
CONTACT:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577
###